CK1a1 (I35C)

CSNK1A1 · Variant type: point · HGVS: p.I35C

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Sunitinib	65.5%	34.5%	91.73
2	Avapritinib	28.0%	72.0%	97.73
3	Darovasertib	23.7%	76.3%	96.99
4	Selpercatinib	16.9%	83.1%	96.72
5	Abrocitinib	16.3%	83.8%	99.50
6	Tucatinib	16.1%	83.9%	99.75
7	Mitapivat	14.6%	85.4%	100.00
8	Defactinib	13.3%	86.7%	92.68
9	Erlotinib	12.3%	87.7%	99.75
10	Quizartinib	10.6%	89.4%	99.50
11	Canertinib	10.2%	89.8%	96.49
12	Fedratinib	8.8%	91.2%	96.21
13	Upadacitinib	8.8%	91.2%	97.98
14	Acalabrutinib	8.4%	91.6%	99.50
15	Palbociclib	8.4%	91.6%	98.75
16	Inavolisib	8.2%	91.8%	100.00
17	Gedatolisib	8.0%	92.0%	99.75
18	Futibatinib	7.3%	92.7%	98.48
19	Zanubrutinib	6.5%	93.5%	98.24
20	Tepotinib	5.9%	94.1%	99.75
21	Asciminib	5.5%	94.5%	100.00
22	Vandetanib	5.0%	95.0%	95.74
23	Lazertinib	5.0%	95.0%	97.47
24	Mobocertinib	4.9%	95.1%	97.22
25	Pexidartinib	4.2%	95.8%	99.49

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Sunitinib	65.5%	—	—
Avapritinib	28.0%	—	—
Darovasertib	23.7%	—	—
Selpercatinib	16.9%	—	—
Abrocitinib	16.3%	—	—
Tucatinib	16.1%	—	—
Mitapivat	14.6%	—	—
Defactinib	13.3%	—	—
Erlotinib	12.3%	—	—
Quizartinib	10.6%	—	—
Canertinib	10.2%	—	—
Fedratinib	8.8%	—	—
Upadacitinib	8.8%	—	—
Acalabrutinib	8.4%	—	—
Palbociclib	8.4%	—	—
Inavolisib	8.2%	—	—
Gedatolisib	8.0%	—	—
Futibatinib	7.3%	—	—
Zanubrutinib	6.5%	—	—
Tepotinib	5.9%	—	—
Asciminib	5.5%	—	—
Vandetanib	5.0%	—	—
Lazertinib	5.0%	—	—
Mobocertinib	4.9%	—	—
Pexidartinib	4.2%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.2ms